版权说明 操作指南
首页 > 成果 > 详情

Pharmacokinetic and Safety Study of Bismuth Potassium Citrate Formulations in Healthy Subjects

认领
导出
Link by DOI
反馈
分享
QQ微信 微博
成果类型:
期刊论文
作者:
Luo, Hong-Yu;Xu, Shuo-Guo;Gao, Li-Chen;Long, Hui-Zhi;Zhou, Zi-Wei;...
通讯作者:
Gao, LC
作者机构:
[Long, Hui-Zhi; Dai, Shang-Ming; Cheng, Yan; Xu, Shuo-Guo; Luo, Hong-Yu; Gao, Li-Chen; Hu, Jin-Da; Li, Feng-Jiao; Zhou, Zi-Wei] Univ South China, Affiliated Changsha Cent Hosp, PhaseClin Trial Ctr 1, Sch Pharm, Changsha, Peoples R China.
[Xu, Shuo-Guo] Hunan Normal Univ, Hosp Changsha 4, Affiliated Changsha Hosp, Changsha, Peoples R China.
[Su, Yu] Hunan Warrant Pharmaceut Co Ltd, Changsha, Peoples R China.
通讯机构:
[Gao, LC ] U
Univ South China, Affiliated Changsha Cent Hosp, PhaseClin Trial Ctr 1, Sch Pharm, Changsha, Peoples R China.
语种:
英文
期刊:
Drugs in R&D
ISSN:
1174-5886
年:
2024
卷:
24
期:
1
页码:
81-87
基金类别:
Changsha Central Hospital Affiliated to University of South China Foundation of key Program; Phase I Clinical Trial Centre, Changsha Central Hospital; University of South China, Changsha, Hunan
机构署名:
本校为第一且通讯机构
院系归属:
药学与生物科学学院
摘要:
BACKGROUND: Potassium bismuth citrate is a gastric mucosal protector and a key drug for treating peptic ulcers. OBJECTIVE: To evaluate the pharmacokinetic characteristics and safety of 120-mg bismuth potassium citrate formulations administered orally under fasting conditions in healthy Chinese subjects. METHOD: A single-center open two-cycle trial was conducted on 12 healthy subjects who received a single oral dose of 120 mg of bismuth potassium citrate. The plasma concentration of bismuth was determined using a validated inductively coupled pl...

反馈

验证码:
看不清楚,换一个
确定
取消

成果认领

标题:
用户 作者 通讯作者
请选择
请选择
确定
取消

提示

该栏目需要登录且有访问权限才可以访问

如果您有访问权限,请直接 登录访问

如果您没有访问权限,请联系管理员申请开通

管理员联系邮箱:yun@hnwdkj.com